Stocktoria
SUPERNUS PHARMACEUTICALS, INC. SUPN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-12-28
SUPERNUS PHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -8.7% | 12.3% | -0.9% | 6.9% | 14.8% |
| Net margin | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% |
| FCF margin | 6.4% | 25.9% | 18.2% | 17.4% | — |
| Return on assets | -2.7% | 5.4% | 0.1% | 3.6% | 3.2% |
| Return on equity | -3.6% | 7.1% | 0.1% | 6.9% | 6.5% |
| Debt / equity | — | — | — | — | 0.46× |
| Current ratio | 1.90 | 2.35 | 1.70 | 1.07 | 1.91 |
| Revenue growth | 8.6% | 8.9% | -8.9% | 15.1% | 11.4% |
Source: SEC EDGAR filings · CIK 0001356576 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.